Hormone refractory prostate cancer (HRPC) is the main reason of poor prognosis of prostate cancer. Expression of prostate specific membrane antigen (PSMA) is specifically high on the HRPC tumor cells while its expression on normal tissues, benign lesions is relatively low. PSMA has attracted great attention and served as potential target for targeted therapy of HRPC. The recent advances in PSMA targeted therapy of HRPC in fields of immnotherapy, gene therapy and internal radiotherapy were reviewed.